Update
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venus Remedies has resubmitted its Q2 FY26 (quarter ended 30 Sept 2025) financial results solely to correct a clerical error: the same UDIN was inadvertently used for both Standalone and Consolidated Limited Review Reports. The correct UDIN for the Consolidated report has now been provided. The filing also includes the full set of results — Standalone Revenue from Operations rose to INR 192.65 Cr (Q2 FY25: INR 169.67 Cr) and H1 PAT jumped to INR 30.95 Cr vs INR 13.71 Cr, while Consolidated H1 Revenue was INR 320.63 Cr with H1 PAT at INR 29.73 Cr. The auditor flagged an Emphasis of Matter noting that the German subsidiary Venus Pharma GmbH's net worth has turned negative by INR 132.10 Lakhs, indicating a going concern uncertainty, and pointed to INR 2,859.72 Lakhs of pending share application money. Management expects the subsidiary's position to stabilise by end of FY25-26.
No material impact on the financials — this is a procedural UDIN fix. However, the embedded results show strong H1 growth and a sharp PAT jump, while the auditor's going concern flag on the German subsidiary remains a key risk for investors to monitor.